Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1986 1
1987 3
1988 3
1989 1
1990 4
1991 1
1992 9
1993 3
1995 3
1996 2
1997 5
1998 3
1999 3
2000 1
2001 1
2002 3
2003 4
2004 1
2005 1
2006 1
2007 2
2008 3
2009 6
2010 9
2011 10
2012 12
2013 12
2014 10
2015 6
2016 4
2017 1
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.
Kwong AD, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, Kempf D, Kieffer TL, Koletzki D, Kukolj G, Lim S, Pilot-Matias T, Lin K, Mani N, Mo H, O'Rear J, Otto M, Parkin N, Pawlotsky JM, Petropoulos C, Picchio G, Ralston R, Reeves JD, Schooley RT, Seiwert S, Standring D, Stuyver L, Sullivan J, Miller V; Forum for Collaborative Human Immunodeficiency Virus Research; HCV Drug Development Advisory Group (HCV DRAG); Sequence Analysis Working Group (SAWG); Phenotype Analysis Working Group (PAWG). Kwong AD, et al. Among authors: picchio g. Gastroenterology. 2011 Mar;140(3):755-60. doi: 10.1053/j.gastro.2011.01.029. Epub 2011 Jan 19. Gastroenterology. 2011. PMID: 21255574 No abstract available.
Telaprevir for retreatment of HCV infection.
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. Zeuzem S, et al. Among authors: picchio g. N Engl J Med. 2011 Jun 23;364(25):2417-28. doi: 10.1056/NEJMoa1013086. N Engl J Med. 2011. PMID: 21696308 Free article. Clinical Trial.
HTLV-I in Argentina.
Bouzas MB, Picchio G, Muchinik G, Campestri R, Cahn P, Perez H, Gallo D, Hanson CV. Bouzas MB, et al. Among authors: picchio g. J Acquir Immune Defic Syndr (1988). 1990;3(7):741-2. J Acquir Immune Defic Syndr (1988). 1990. PMID: 2352127 No abstract available.
EBV-induced human B cell lymphomas in hu-PBL-SCID mice.
Mosier DE, Picchio GR, Kirven MB, Garnier JL, Torbett BE, Baird SM, Kobayashi R, Kipps TJ. Mosier DE, et al. Among authors: picchio gr. AIDS Res Hum Retroviruses. 1992 May;8(5):735-40. AIDS Res Hum Retroviruses. 1992. PMID: 1325170 Review.
Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B.
Yuen MF, Berliba E, Sukeepaisarnjaroen W, Ahn SH, Tanwandee T, Lim YS, Kim YJ, Poovorawan K, Tangkijvanich P, Schwabe C, Eley T, Brown J, Lee ACH, Thi EP, Paratala B, Mani N, Sofia MJ, Picchio G, Sims KD, Gane EJ. Yuen MF, et al. Among authors: picchio g. Hepatol Commun. 2022 Dec;6(12):3457-3472. doi: 10.1002/hep4.2095. Epub 2022 Oct 4. Hepatol Commun. 2022. PMID: 36194181 Free PMC article. Clinical Trial.
Modeling viral evolutionary dynamics after telaprevir-based treatment.
Haseltine EL, De Meyer S, Dierynck I, Bartels DJ, Ghys A, Davis A, Zhang EZ, Tigges AM, Spanks J, Picchio G, Kieffer TL, Sullivan JC. Haseltine EL, et al. Among authors: picchio g. PLoS Comput Biol. 2014 Aug 7;10(8):e1003772. doi: 10.1371/journal.pcbi.1003772. eCollection 2014 Aug. PLoS Comput Biol. 2014. PMID: 25101970 Free PMC article.
119 results